Abstract
Dengue is the most prevalent mosquito-borne viral disease in humans, and cases are continuing to rise globally. In particular, islands in the Caribbean have experienced more frequent outbreaks, and all four dengue virus (DENV) serotypes have been reported in the region, leading to hyperendemicity and increased rates of severe disease. However, there is significant variability regarding virus surveillance and reporting between islands, making it difficult to obtain an accurate understanding of the epidemiological patterns in the Caribbean. To investigate this, we used travel surveillance and genomic epidemiology to reconstruct outbreak dynamics, DENV serotype turnover, and patterns of spread within the region from 2009-2022. We uncovered two recent DENV-3 introductions from Asia, one of which resulted in a large outbreak in Cuba, which was previously under-reported. We also show that while outbreaks can be synchronized between islands, they are often caused by different serotypes. Our study highlights the importance of surveillance of infected travelers to provide a snapshot of local introductions and transmission in areas with limited local surveillance and suggests that the recent DENV-3 introductions may pose a major public health threat in the region.
Competing Interest Statement
NDG is a paid consultant for BioNTech.
Funding Statement
This publication was made possible by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number DP2AI176740 (NDG), CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science, a component of the NIH (CBFV), the NIH T32AI055403 (AS), The Dominican Ministry of Higher Education and Technology Fund (FONDOCYT-2022-1B3-069), the National Institute of General Medical Sciences R21GM142011 (SFM), and through a Cooperative Agreement between the US Centers for Disease Control and Prevention (CDC) and the International Society of Travel Medicine (ISTM) (Federal Award Number: 1 U01CK000632-01-00). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the CDC, NIH, or FDOH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards (IRB) from the FDOH, Universidad Iberoamerican (UNIBE), Florida Gulf Coast University, and the Yale University Human Research Protection Program determined that pathogen genomic sequencing of de-identified remnant diagnostic samples as conducted in this study is not research involving human subjects.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All DENV genomes and sequencing data are available on BioProject PRJNA951702. All code and model results are available at: https://github.com/grubaughlab/2023_paper_DENV-travelers
